RxDoctor Payments Data

Nakul Goyal, MD

Internal Medicine · Silver Spring, MDNPI 1194738567

Payments from drug & device makers

$2,302in general payments, 2019–2025

Across 130 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$584
  • Novo Nordisk$364
  • Pfizer$300
  • Boehringer Ingelheim$132
  • Johnson & Johnson$132
  • Amarin Pharma, Inc.$106
  • plus $684 from 13 others

What the payments were for

  • Food & beverage$2,302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,302 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$211,126
Medicare patients
418
Services billed
3,123

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$109,207
JanuviaSitagliptin Phosphate53$58,737
EliquisApixaban53$54,554
Tresiba Flextouch U-200Insulin Degludec15$39,644
FarxigaDapagliflozin Propanediol32$34,191
OzempicSemaglutide23$27,257
TradjentaLinagliptin20$17,813
XareltoRivaroxaban18$15,202
RybelsusSemaglutide12$11,437
Janumet XrSitagliptin Phos/Metformin Hcl14$8,338
EntrestoSacubitril/Valsartan13$7,082
Atorvastatin Calcium527$6,711
Breo ElliptaFluticasone/Vilanterol11$6,305
DuleraMometasone/Formoterol12$4,046
Rosuvastatin Calcium171$3,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$132$127,020111 claims
MerckJanuvia, Janumet Xr, Dulera$51$71,12179 claims
PfizerEliquis$300$54,55453 claims
Novo NordiskOzempic, Rybelsus$364$38,69435 claims
AstraZenecaFarxiga$584$34,19132 claims
Johnson & JohnsonXarelto$132$15,20218 claims
GSKBreo Ellipta$89$6,30511 claims
AbbVieSynthroid$86$1,11836 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →